DOCSLIB.ORG

Toxicology Drug Testing Panels

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Toxicology Drug Testing Panels RTXMSJ06008UAH Toxicology Drug Testing Panels Document Number: RTXMSJ06008UAH Revision Number: 1.73 Document Type: Attachment Effective Date: 5/3/2021 3:08:59 PM Location: AHS Laboratory Services\Document Administration\Toxicology and Trace Elements\17. Drug Testing LCMSMS\1. Drug Testing LCMSMS Job Aids RTXMSJ06008UAH Toxicology Drug Testing Panels Urine Opioid Dependency Panel 1 (UODP) CUT-OFF DRUG CLASS COMMON TRADE NAMES INTERPRETIVE CONCENTRATION2 ANALYTE DETECTED (STREET NAME) NOTES (NG/ML) Amphetamines Adderall, Dexedrine, Vyvanse, A prescription drug; also a metabolite of Amphetamine 250 Lisdexamfetamine methamphetamine (Speed, Bennies, Crystal Meth, Metabolite of Selegiline; Metabolized to Methamphetamine 250 Uppers) amphetamine Metabolite of Methylenedioxyamphetamine (MDA) 250 methylenedioxymethamphetamine Methylenedioxymethamphetamine (Ecstasy, MDMA) Metabolized to methylenedioxyamphetamine 250 Page 1 of 15 RTXMSJ06008UAH Toxicology Drug Testing Panels Rev: 1.73 CUT-OFF DRUG CLASS COMMON TRADE NAMES INTERPRETIVE CONCENTRATION2 ANALYTE DETECTED (STREET NAME) NOTES (NG/ML) Benzodiazepines Flubromazepam prescription not available in Flubromazepam 50 Canada 7-Aminoclonazepam Metabolite of clonazepam (Rivotril) 50 7-Aminonitrazepam Metabolite of nitrazepam (Mogadon) 50 Alphahydroxyalprazolam Metabolite of alprazolam (Xanax) 50 Alphahydroxytriazolam Metabolite of triazolam (Halcion) 50 Bromazepam Lectopam 50 Clobazam Frisium Metabolized to norclobazam 50 o Norclobazam Metabolite of clobazam 50 Metabolite of chlordiazepoxide (Librium); Demoxepam 50 further metabolized to nordiazepam Page 2 of 15 RTXMSJ06008UAH Toxicology Drug Testing Panels Rev: 1.73 CUT-OFF DRUG CLASS COMMON TRADE NAMES INTERPRETIVE CONCENTRATION2 ANALYTE DETECTED (STREET NAME) NOTES (NG/ML) Benzodiazepines continued Metabolized to nordiazepam, temazepam, Diazepam Valium 50 oxazepam Metabolized to 3-hydroxyetizolam, Etizolam 50 prescription not available in Canada Metabolite of etizolam. Etizolam prescription o 3-Hydroxyetizolam 50 not available in Canada Flubromazolam Prescription not available in Canada 50 Lorazepam Ativan 50 Midazolam Versed Metabolized to 1-hydroxymidazolam 50 o 1-Hydroxymidazolam Metabolite of midazolam 50 Metabolite of diazepam (Valium) and Nordiazepam chlordiazepoxide (Librium); further 50 metabolized to oxazepam Metabolite of diazepam, temazepam, Oxazepam Serax 50 chlordiazepoxide Metabolite of diazepam; metabolized to Temazepam Restoril 50 oxazepam Cocaine Related Compounds Benzoylecgonine Metabolite of cocaine 150 Page 3 of 15 RTXMSJ06008UAH Toxicology Drug Testing Panels Rev: 1.73 CUT-OFF DRUG CLASS COMMON TRADE NAMES INTERPRETIVE CONCENTRATION2 ANALYTE DETECTED (STREET NAME) NOTES (NG/ML) Opioids 6-Acetylmorphine 6-monoacetylmorphine (6-MAM) Heroin metabolite 5 Tylenol with codeine, Tylenol No. 2, Codeine Tylenol No. 3, Tylenol No. 4, codeine Metabolized to morphine and hydrocodone 50 phosphate and others Metabolite of codeine; metabolized to MS Contin, M-Eslon, Kadian and Morphine hydromorphone; potentially detected after 150 others poppy seed consumption Metabolite of codeine; metabolized to Hydrocodone Vicodin 50 hydromorphone Hydromorphone Dilaudid, Hydromorph Contin, Jurnista Metabolite of hydrocodone 50 Oxycontin, OxyNeo, Percocet, Oxycodone Metabolized to oxymorphone 50 Percodan Metabolite of oxycodone, prescription not Oxymorphone Not Reported available in Canada Fentanyl Duragesic Metabolized to norfentanyl 5 o Norfentanyl Metabolite of fentanyl 5 Norcarfentanil Metabolite of carfentanil and remifentanil 0.5 Buprenorphine Butrans, Suboxone, Belbuca Metabolized to norbuprenorphine 10 o Norbuprenorphine Metabolite of buprenorphine 10 Methadone Methadose Metabolized to EDDP 50 3 o EDDP Metabolite of methadone 50 Page 4 of 15 RTXMSJ06008UAH Toxicology Drug Testing Panels Rev: 1.73 1. Sample hydrolysis performed prior to analysis by liquid chromatography/mass spectrometry (LC-MS/MS) allowing detection of both free and conjugated drug. A positive result does not give any indication as to level of impairment/intoxication, route of administration or ingested dose. Determining concentration of drug (i.e. the drug level) in urine does not overcome these limitations. Concentrations are NOT reported. A negative result does not necessarily mean the urine is drug free. A negative result may mean: the sample is drug free or drugs are present but were not at or above the cut-off concentrations listed or the drug present in the sample is not detected by this method. 2. The cut-off concentration is the concentration that distinguishes whether a drug is reported as detected or not detected. 3. EDDP = 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine Page 5 of 15 RTXMSJ06008UAH Toxicology Drug Testing Panels Rev: 1.73 Urine General Toxicology Panel 1 (UGTP) CUT-OFF DRUG CLASS COMMON TRADE NAMES INTERPRETIVE CONCENTRATION2 ANALYTE DETECTED (STREET NAME) NOTES (NG/ML) Amphetamines Adderall, Dexedrine, Vyvanse, A prescription drug; also a metabolite of Amphetamine 250 Lisdexamfetamine methamphetamine (Speed, Bennies, Crystal Meth, Metabolite of Selegiline; Metabolized to Methamphetamine 250 Uppers) amphetamine Metabolite of Methylenedioxyamphetamine (MDA) 250 methylenedioxymethamphetamine Methylenedioxymethamphetamine (Ecstasy, MDMA) Metabolized to methylenedioxyamphetamine 250 Metabolite of Paramethoxyamphetamine (PMA) 50 paramethoxymethamphetamine Paramethoxymethamphetamine (PMMA) Metabolized to paramethoxyamphetamine 50 Analgesics Tapentadol Nucynta 50 Tramadol Tramacet Metabolized to O-desmethyltramadol 50 o O-desmethyltramadol Metabolite of tramadol 50 Anesthetics Ketamine Metabolized to norketamine 100 o Norketamine Metabolite of ketamine 100 Page 6 of 15 RTXMSJ06008UAH Toxicology Drug Testing Panels Rev: 1.73 CUT-OFF DRUG CLASS COMMON TRADE NAMES INTERPRETIVE CONCENTRATION2 ANALYTE DETECTED (STREET NAME) NOTES (NG/ML) Anticonvulsants Gabapentin Neurontin 10,000 Antihistamine Diphenhydramine\ Dimenhydrinate is the 8-chlorotheophylline 50 Dimenhydrinate salt of diphenhydramine Barbiturates Fiorinal (with codeine in some Butalbital 300 preparations) Phenobarbital Luminal, phenobarbitone 300 Benzodiazepines Flubromazepam prescription not available in Flubromazepam 50 Canada 7-Aminoclonazepam Metabolite of clonazepam (Rivotril) 50 7-Aminonitrazepam Metabolite of nitrazepam (Mogadon) 50 Alphahydroxyalprazolam Metabolite of alprazolam (Xanax) 50 Alphahydroxytriazolam Metabolite of triazolam (Halcion) 50 Page 7 of 15 RTXMSJ06008UAH Toxicology Drug Testing Panels Rev: 1.73 CUT-OFF DRUG CLASS COMMON TRADE NAMES INTERPRETIVE CONCENTRATION2 ANALYTE DETECTED (STREET NAME) NOTES (NG/ML) Benzodiazepines continued Bromazepam Lectopam 50 Clobazam Frisium Metabolized to norclobazam 50 o Norclobazam Metabolite of clobazam 50 Metabolite of chlordiazepoxide (Librium); Demoxepam 50 further metabolized to nordiazepam Metabolized to nordiazepam, temazepam, Diazepam Valium 50 oxazepam Metabolized to 3-hydroxyetizolam, Etizolam 50 prescription not available in Canada Metabolite of etizolam. Etizolam prescription o 3-Hydroxyetizolam 50 not available in Canada Flubromazolam Prescription not available in Canada 50 Lorazepam Ativan 50 Midazolam Versed Metabolized to 1-hydroxymidazolam 50 o 1-Hydroxymidazolam Metabolite of midazolam 50 Metabolite of diazepam (Valium) and Nordiazepam chlordiazepoxide (Librium); further 50 metabolized to oxazepam Metabolite of diazepam, temazepam, Oxazepam Serax 50 chlordiazepoxide Metabolite of diazepam; metabolized to Temazepam Restoril 50 oxazepam Page 8 of 15 RTXMSJ06008UAH Toxicology Drug Testing Panels Rev: 1.73 CUT-OFF DRUG CLASS COMMON TRADE NAMES INTERPRETIVE CONCENTRATION2 ANALYTE DETECTED (STREET NAME) NOTES (NG/ML) Cannabinoids Marijuana Metabolite (THC COOH) Sativex (Cannabis, Cannabinoids, Metabolite of tetrahydrocannabinol (THC) 15 (11-nor-9-tetrahydrocannabinol-9- Weed, Grass, THC) carboxylic acid) Cutting Agents Cutting agent – may cause profound Levamisole 50 neutropenia Phenacetin Cutting agent 25 Xylazine Cutting agent 50 Cocaine and Related Compounds Cocaine (crack, blow, snow) Metabolized to a variety of metabolites 50 Benzoylecgonine Metabolite of cocaine 150 Metabolite arising from simultaneous use of Cocaethylene 25 cocaine and ethanol Page 9 of 15 RTXMSJ06008UAH Toxicology Drug Testing Panels Rev: 1.73 CUT-OFF DRUG CLASS COMMON TRADE NAMES INTERPRETIVE CONCENTRATION2 ANALYTE DETECTED (STREET NAME) NOTES (NG/ML) Opioids 6-Acetylmorphine 6-monoacetylmorphine (6-MAM) Metabolite of heroin (diacetylmorphine) 5 Tylenol with codeine, Tylenol No. 2, Codeine Tylenol No. 3, Tylenol No. 4, codeine Metabolized to morphine and hydrocodone 50 phosphate and others Metabolite of codeine; metabolized to MS Contin, M-Eslon, Kadian and Morphine hydromorphone; potentially detected after 150 others poppy seed consumption Metabolite of codeine; metabolized to Hydrocodone Vicodin 50 hydromorphone o Norhydrocodone Metabolite of hydrocodone 50 Hydromorphone Dilaudid, Hydromorph Contin, Jurnista Metabolite of hydrocodone 50 Oxycontin, OxyNeo, Percocet, Metabolized to noroxycodone and Oxycodone 50 Percodan oxymorphone o Noroxycodone Metabolite of oxycodone 50 Oxymorphone Prescription not available in Canada Metabolite of oxycodone Not Reported Metabolite of oxymorphone and naloxone; o Noroxymorphone 50 naltrexone pharmaceutical impurity Page 10 of 15 RTXMSJ06008UAH Toxicology Drug Testing Panels Rev: 1.73 CUT-OFF DRUG CLASS COMMON TRADE NAMES
Load more

Recommended publications
  • Drug and Alcohol Withdrawal Clinical Practice Guidelines - NSW
    Guideline Drug and Alcohol Withdrawal Clinical Practice Guidelines - NSW Summary To provide the most up-to-date knowledge and current level of best practice for the treatment of withdrawal from alcohol and other drugs such as heroin, and other opioids, benzodiazepines, cannabis and psychostimulants. Document type Guideline Document number GL2008_011 Publication date 04 July 2008 Author branch Centre for Alcohol and Other Drugs Branch contact (02) 9424 5938 Review date 18 April 2018 Policy manual Not applicable File number 04/2766 Previous reference N/A Status Active Functional group Clinical/Patient Services - Pharmaceutical, Medical Treatment Population Health - Pharmaceutical Applies to Area Health Services/Chief Executive Governed Statutory Health Corporation, Board Governed Statutory Health Corporations, Affiliated Health Organisations, Affiliated Health Organisations - Declared Distributed to Public Health System, Ministry of Health, Public Hospitals Audience All groups of health care workers;particularly prescribers of opioid treatments Secretary, NSW Health Guideline Ministry of Health, NSW 73 Miller Street North Sydney NSW 2060 Locked Mail Bag 961 North Sydney NSW 2059 Telephone (02) 9391 9000 Fax (02) 9391 9101 http://www.health.nsw.gov.au/policies/ space space Drug and Alcohol Withdrawal Clinical Practice Guidelines - NSW space Document Number GL2008_011 Publication date 04-Jul-2008 Functional Sub group Clinical/ Patient Services - Pharmaceutical Clinical/ Patient Services - Medical Treatment Population Health - Pharmaceutical
    [Show full text]
  • Understanding Benzodiazephine Use, Abuse, and Detection
    Siemens Healthcare Diagnostics, the leading clinical diagnostics company, is committed to providing clinicians with the vital information they need for the accurate diagnosis, treatment and monitoring of patients. Our comprehensive portfolio of performance-driven systems, unmatched menu offering and IT solutions, in conjunction with highly responsive service, is designed to streamline workflow, enhance operational efficiency and support improved patient care. Syva, EMIT, EMIT II, EMIT d.a.u., and all associated marks are trademarks of General Siemens Healthcare Diagnostics Inc. All Drugs other trademarks and brands are the Global Division property of their respective owners. of Abuse Siemens Healthcare Product availability may vary from Diagnostics Inc. country to country and is subject 1717 Deerfield Road to varying regulatory requirements. Deerfield, IL 60015-0778 Please contact your local USA representative for availability. www.siemens.com/diagnostics Siemens Global Headquarters Global Siemens Healthcare Headquarters Siemens AG Understanding Wittelsbacherplatz 2 Siemens AG 80333 Muenchen Healthcare Sector Germany Henkestrasse 127 Benzodiazephine Use, 91052 Erlangen Germany Abuse, and Detection Telephone: +49 9131 84 - 0 www.siemens.com/healthcare www.usa.siemens.com/diagnostics Answers for life. Order No. A91DX-0701526-UC1-4A00 | Printed in USA | © 2009 Siemens Healthcare Diagnostics Inc. Syva has been R1 R2 a leading developer N and manufacturer of AB R3 X N drugs-of-abuse tests R4 for more than 30 years. R2 C Now part of Siemens Healthcare ® Diagnostics, Syva boasts a long and Benzodiazepines have as their basic chemical structure successful track record in drugs-of-abuse a benzene ring fused to a seven-membered diazepine ring. testing, and leads the industry in the All important benzodiazepines contain a 5-aryl substituent ring (ring C) and a 1,4–diazepine ring.
    [Show full text]
  • Risk Based Requirements for Medicines Handling
    Risk based requirements for medicines handling Including requirements for Schedule 4 Restricted medicines Contents 1. Introduction 2 2. Summary of roles and responsibilities 3 3. Schedule 4 Restricted medicines 4 4. Medicines acquisition 4 5. Storage of medicines, including control of access to storage 4 5.1. Staff access to medicines storage areas 5 5.2. Storage of S4R medicines 5 5.3. Storage of S4R medicines for medical emergencies 6 5.4. Access to storage for S4R and S8 medicines 6 5.5. Pharmacy Department access, including after hours 7 5.6. After-hours access to S8 medicines in the Pharmacy Department 7 5.7. Storage of nitrous oxide 8 5.8. Management of patients’ own medicines 8 6. Distribution of medicines 9 6.1. Distribution outside Pharmacy Department operating hours 10 6.2. Distribution of S4R and S8 medicines 10 7. Administration of medicines to patients 11 7.1. Self-administration of scheduled medicines by patients 11 7.2. Administration of S8 medicines 11 8. Supply of medicines to patients 12 8.1. Supply of scheduled medicines to patients by health professionals other than pharmacists 12 9. Record keeping 13 9.1. General record keeping requirements for S4R medicines 13 9.2. Management of the distribution and archiving of S8 registers 14 9.3. Inventories of S4R medicines 14 9.4. Inventories of S8 medicines 15 10. Destruction and discards of S4R and S8 medicines 15 11. Management of oral liquid S4R and S8 medicines 16 12. Cannabis based products 17 13. Management of opioid pharmacotherapy 18 14.
    [Show full text]
  • Socio-Demographic and Clinical Characteristics of Benzodiazepine Long-Term Users: Results from a Tertiary Care Center ⁎ F
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Florence Research Available online at www.sciencedirect.com ScienceDirect Comprehensive Psychiatry 69 (2016) 211–215 www.elsevier.com/locate/comppsych Socio-demographic and clinical characteristics of benzodiazepine long-term users: Results from a tertiary care center ⁎ F. Coscia, , G. Mansuetoa, M. Faccinib, R. Casarib, F. Lugobonib aDepartment of Health Sciences, University of Florence, via di San Salvi 12, 50135, Florence, Italy bAddiction Unit, Verona University Hospital, piazzale Aristide Stefani 1, 37126, Verona, Italy Abstract Objective: The use of benzodiazepines (BDZs) represents a critical issue since a long-term treatment may lead to dependence. This study aimed at evaluating socio-demographic and clinical characteristics of BZD long-term users who followed a detoxification program at a tertiary care center. Method: Two hundred-five inpatients were evaluated. Socio-demographic (e.g., gender, age, education) and clinical information (e.g., BZD used, dose, reason of prescription) was collected. BZDs dose was standardized as diazepam dose equivalents and was compared via the Defined Daily Dose (DDD). Chi-square, Fisher test, ANOVA and Bonferroni analyses were performed. Results: Females were more frequently BDZ long-term users than males. Hypnotic BZDs were frequently prescribed for problems different from sleep disturbances. Lorazepam, alprazolam, and lormetazepam were the most prescribed drugs. Lorazepam was more frequently used by males, consumed for a long period, in pills, and prescribed for anxiety. Lormetazepam was more frequently consumed by females with a high school education, having a psychiatric disorder, taken in drops and prescribed for insomnia.
    [Show full text]
  • Benzodiazepines
    Benzodiazepines Using benzodiazepines in Children and Adolescents Overview Benzodiazepines are group of medications used to treat several different conditions. Some examples of these medications include: lorazepam (Ativan®); clonazepam (Rivotril®); alprazolam (Xanax®) and oxazepam (Serax®). Other benzodiazepine medications are available, but are less commonly used in children and adolescents. What are benzodiazepines used for? Benzodiazepines may be used for the following conditions: • anxiety disorders: generalized anxiety disorder; social anxiety disorder; post-traumatic stress disorder (PTSD); panic attacks/disorder; excessive anxiety prior to surgery • sleep disorders: trouble sleeping (insomnia); waking up suddenly with great fear (night terrors); sleepwalking • seizure disorders (epilepsy) • alcohol withdrawal • treatment of periods of extreme slowing or excessive purposeless motor activity (catatonia) Your doctor may be using this medication for another reason. If you are unclear why this medication is being prescribed, please ask your doctor. How do benzodiazepines work? Benzodiazepines works by affecting the activity of the brain chemical (neurotransmitter) called GABA. By enhancing the action of GABA, benzodiazepines have a calming effect on parts of the brain that are too excitable. This in turn helps to manage anxiety, insomnia, and seizure disorders. How well do benzodiazepines work in children and adolescents? When used to treat anxiety disorders, benzodiazepines decrease symptoms such as nervousness, fear, and excessive worrying. Benzodiazepines may also help with the physical symptoms of anxiety, including fast or strong heart beat, trouble breathing, dizziness, shakiness, sweating, and restlessness. Typically, benzodiazepines are prescribed to manage anxiety symptoms that are uncomfortable, frightening or interfere with daily activities for a short period of time before conventional anti-anxiety treatments like cognitive-behavioural therapy or anti-anxiety takes effect.
    [Show full text]
  • Information to Users
    Confirmation of urinary benzodiazepines by gas chromatography/mass spectrometry Item Type text; Thesis-Reproduction (electronic) Authors West, Robert E., 1952- Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 06/10/2021 02:51:08 Link to Item http://hdl.handle.net/10150/277228 INFORMATION TO USERS The most advanced technology has been used to photo­ graph and reproduce this manuscript from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are re­ produced by sectioning the original, beginning at the upper left-hand corner and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book.
    [Show full text]
  • Benzodiazepine Group ELISA Kit
    Benzodiazepine Group ELISA Kit Benzodiazepine Background Since their introduction in the 1960s, benzodiazepines have been widely prescribed for the treatment of anxiety, insomnia, muscle spasms, alcohol withdrawal, and seizure-prevention as they are depressants of the central nervous system. Despite the fact that they are highly effective for their intended use, benzodiazepines are prescribed with caution as they can be highly addictive. In fact, researchers at NIDA (National Institute on Drug Abuse) have shown that addiction for benzodiazepines is similar to that of opioids, cannabinoids, and GHB. Common street names of benzodiazepines include “Benzos” and “Downers”. The five most encountered benzodiazepines on the illicit market are alprazolam (Xanax), lorazepam (Ativan), clonazepam (Klonopin), diazepam (Valium), and temazepam (Restori). The method of abuse is typically oral or snorted in crushed form. The DEA notes a particularly high rate of abuse among heroin and cocaine abusers. Designer benzodiazepines are currently offered in online shops selling “research chemicals”, providing drug abusers an alternative to prescription-only benzodiazepines. Data defining pharmacokinetic parameters, drug metabolisms, and detectability in biological fluids is limited. This lack of information presents a challenge to forensic laboratories. Changes in national narcotics laws in many countries led to the control of (phenazepam and etizolam), which were marketed by pharmaceutical companies in some countries. With the control of phenazepam and etizolam, clandestine laboratories have begun researching and manufacturing alternative benzodiazepines as legal substitutes. Delorazepam, diclazepam, pyrazolam, and flubromazepam have emerged as compounds in this class of drugs. References Drug Enforcement Administration, Office of Diversion Control. “Benzodiazepines.” http://www.deadiversion.usdoj.gov/drugs_concern/benzo_1.
    [Show full text]
  • Analytical Methods for Determination of Benzodiazepines. a Short Review
    Cent. Eur. J. Chem. • 12(10) • 2014 • 994-1007 DOI: 10.2478/s11532-014-0551-1 Central European Journal of Chemistry Analytical methods for determination of benzodiazepines. A short review Review Article Paulina Szatkowska1, Marcin Koba1*, Piotr Kośliński1, Jacek Wandas1, Tomasz Bączek2,3 1Department of Toxicology, Faculty of Pharmacy, Collegium Medicum of Nicolaus Copernicus University, 85-089 Bydgoszcz, Poland 2Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Gdańsk, 80-416 Gdańsk, Poland 3Institute of Health Sciences, Division of Human Anatomy and Physiology, Pomeranian University of Słupsk, 76-200 Słupsk, Poland Received 16 July 2013; Accepted 6 February 2014 Abstract: Benzodiazepines (BDZs) are generally commonly used as anxiolytic and/or hypnotic drugs as a ligand of the GABAA-benzodiazepine receptor. Moreover, some of benzodiazepines are widely used as an anti-depressive and sedative drugs, and also as anti-epileptic drugs and in some cases can be useful as an adjunct treatment in refractory epilepsies or anti-alcoholic therapy. High-performance liquid chromatography (HPLC) methods, thin-layer chromatography (TLC) methods, gas chromatography (GC) methods, capillary electrophoresis (CE) methods and some of spectrophotometric and spectrofluorometric methods were developed and have been extensively applied to the analysis of number of benzodiazepine derivative drugs (BDZs) providing reliable and accurate results. The available chemical methods for the determination of BDZs in biological materials and pharmaceutical formulations are reviewed in this work. Keywords: Analytical methods • Benzodiazepines • Drugs analysis • Pharmaceutical formulations © Versita Sp. z o.o. 1. Introduction and long). For this reason, an application of these drugs became broader allowing their utility to a larger extent, Benzodiazepines have been first introduced into medical and at the same time, problems related to drug abuse practice in the 60s of the last century.
    [Show full text]
  • The Misuse of Benzodiazepines Among High-Risk Opioid Users in Europe
    EMBARGO — 7 JUNE 7. 6. 2018 UPDATED 11:30 Central European Time/CET (10:30 Western European Time/WET/Lisbon) Proof - 28 May 2018 not for circulation PERSPECTIVES ON DRUGS The misuse of benzodiazepines among high-risk opioid users in Europe Benzodiazepines are a widely prescribed I Introduction group of medicines with a range of clinical uses that include treating Benzodiazepines have a range of clinical uses and are among the most commonly prescribed medicines globally. anxiety, insomnia and managing alcohol They are useful in the short-term treatment of anxiety and withdrawal. This group of medicines is insomnia, and in managing alcohol withdrawal (Medicines often misused by high-risk opioid users, and Healthcare Products Regulatory Agency, 2015). Like all medicines, benzodiazepines can produce side effects. They and this is associated with considerable may also be misused, which we define as use without a morbidity and mortality. This paper prescription from a medical practitioner or, if prescribed, when describes the impact of benzodiazepines they are used outside accepted medical practice or guidelines. misuse on the health and treatment of While the misuse of benzodiazepines has been identified high-risk opioid users. as a concern for large groups in the general population, for example, among elderly people and women, this analysis focuses specifically on misuse among high-risk opioid users (1), a group of people among whom these medicines have been linked with severe treatment challenges and implicated in considerable numbers of drug-related deaths. It is important to stress that much benzodiazepine prescribing to high-risk drug users is done with legitimate therapeutic aims in mind.
    [Show full text]
  • ETIZOLAM Critical Review Report Agenda Item 4.13
    ETIZOLAM Critical Review Report Agenda Item 4.13 Expert Committee on Drug Dependence Thirty-ninth Meeting Geneva, 6-10 November 2017 39th ECDD (2017) Agenda item 4.13 Etizolam Page 2 of 20 39th ECDD (2017) Agenda item 4.13 Etizolam Contents Acknowledgements.................................................................................................................................. 5 Summary...................................................................................................................................................... 6 1. Substance identification ....................................................................................................................... 7 A. International Nonproprietary Name (INN).......................................................................................................... 7 B. Chemical Abstract Service (CAS) Registry Number .......................................................................................... 7 C. Other Chemical Names ................................................................................................................................................... 7 D. Trade Names ....................................................................................................................................................................... 7 E. Street Names ....................................................................................................................................................................... 8 F. Physical Appearance
    [Show full text]
  • ETIZOLAM in POST-MORTEM CASES Joanna Hockenhull1
    ETIZOLAM IN POST-MORTEM CASES Joanna Hockenhull1 1Toxicology Unit, Faculty of Medicine, Imperial College London. INTRODUCTION: Etizolam [4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine] is a benzodiazepine analogue. The benzene ring is replaced with a thiophene ring making the drug a ‘thienodiazepine’. This poster reviews four post-mortem cases, submitted to Imperial College Toxicology Unit, in which etizolam was detected in the post-mortem, femoral blood. RESULTS: The findings are summarised in the tables below. Medicinal use: • Widely available in Japan (Depas, Sedekopan ) and India (Etilaam, Etizola). CASE 1: CASE 2: • Adult daily doses range from 0.5 – 3.0 milligrams. • 52 year old female • 47 year old male • Used in short-term treatment of insomnia or anxiety. 1 • Found dead in church yard surrounded by empty • History of alcohol abuse and depression 2 • Acts as a full agonist at the benzodiazepine receptor. medication packets • Has potent hypnotic properties comparable with other short-acting • Found dead in bed surrounded by empty medication benzodiazepines. Drug Blood Concentration packets. • (Etizolam has anxiolytic effects six times greater than diazepam). 3 ETIZOLAM 0.09 µg/ml Drug Blood Concentration 4 • Thought to have reduced tolerance/dependence than classical benzodiazepines. Diphenhydramine High therapeutic ETIZOLAM 0.46 µg/ml FIGURE 1: Structure of Etizolam • However, long-term use may produce similar side-effects to benzodiazepines: Venlafaxine 7.10 µg/ml 5 Amitriptyline High therapeutic addiction, hostile behaviour, memory loss and severe withdrawal. Mirtazapine 1.41 µg/ml Illicit use: Ethanol <10 mg/dL Citalopram 0.79 µg/ml • Etizolam is not licenced as a medicine in the UK.
    [Show full text]
  • Flualprazolam Sample Type: Biological Fluid
    Flualprazolam Sample Type: Biological Fluid Latest Revision: June 25, 2019 Date of Report: June 25, 2019 1. GENERAL INFORMATION IUPAC Name: 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3- a][1,4]benzodiazepine InChI String: InChI=1S/C17H12ClFN4/c1-10-21-22-16-9-20-17(12-4-2-3-5- 14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3 CFR: Not Scheduled (06/2019) CAS# 28910-91-0 Synonyms: 2’-Fluoro Alprazolam, ortho-Fluoro Alprazolam Source: NMS Labs – Toxicology Department 2. CHEMICAL DATA Chemical Molecular Molecular Exact Mass Analyte Formula Weight Ion (M) [M+H]+ Flualprazolam C17H12ClFN4 326.75 326 327.0807 Important Note: All identifications were made based on evaluation of analytical data (LC-QTOF) in comparison to analysis of acquired reference material. Report Prepared By: Alex J. Krotulski, MSFS, and Barry K. Logan, PhD, F-ABFT 3. SAMPLE HISTORY Flualprazolam has been identified in three cases since March 2018. The geographical and demographic breakdown is below: Geographical Location: Pennsylvania (n=2), Indiana (n=1) Biological Sample: Blood (n=3) Date of First: Collection: March 8, 2018 Receipt: March 10, 2018 Date of Most Recent: Collection: June 3, 2019 Receipt: June 7, 2019 Additional NPS: Etizolam (n=2), Clonazolam (n=1), Flubromazolam (n=1) 4. BRIEF DESCRIPTION Flualprazolam is classified as a novel benzodiazepine, although its synthesis and activity have been previously described in the literature.1 Benzodiazepines are central nervous system depressants. Novel benzodiazepines, often pirated from early drug discovery or pharmaceutical studies, have appeared on novel and illicit drug markets in recent years.
    [Show full text]